7-azidomethyl-spiro[3.5]nonane

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 7-azidomethyl-spiro[3.5]nonane
• 英文别名: 7-(Azidomethyl)spiro[3.5]nonane；7-(azidomethyl)spiro[3.5]nonane
• 化学式: C₁₀H₁₇N₃
• 分子量: 179.265
• InChiKey: WPELDUYXMGBWLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  14.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-azidomethyl-spiro[3.5]nonane 在 三苯基膦 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 23.0h， 生成 7-氨甲基-螺环[3.5]壬烷
  参考文献：
  名称：

  Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2

  摘要：

  We describe here orally active and brain-penetrant cathepsin S selective inhibitors, which are virtually devoid of hERG K(+) channel affinity, yet exhibit nanomolar potency against cathepsin S and over 100-fold selectivity to cathepsin L. The new non-peptidic inhibitors are based on a 2-cyanopyrimidine scaffold bearing a spiro[3.5] non-6-yl-methyl amine at the 4-position. The brain-penetrating cathepsin S inhibitors demonstrate potential clinical utility for the treatment of multiple sclerosis and neuropathic pain. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.067
• 作为产物：
  描述：

  在 sodium azide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 7-azidomethyl-spiro[3.5]nonane
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS
  [FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE LA CATHEPSINE S

  摘要：

  本发明涉及使用式(I)的2-氰基嘧啶化合物，其中R1、R2、R3和X如规范和权利要求中定义的那样，以自由形式或盐形式，并在可能的情况下以互变异构形式，作为猫hepsin S活性的抑制剂。

  公开号：

  WO2006018284A1

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE LA CATHEPSINE S
  申请人：NOVARTIS AG

  公开号：WO2006018284A1

  公开（公告）日：2006-02-23

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula (I), wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and , where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式(I)的2-氰基嘧啶化合物，其中R1、R2、R3和X如规范和权利要求中定义的那样，以自由形式或盐形式，并在可能的情况下以互变异构形式，作为猫hepsin S活性的抑制剂。
• COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS
  申请人：Hart Terance William

  公开号：US20090048230A1

  公开（公告）日：2009-02-19

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R 1 , R 2 , R 3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式中R1、R2、R3和X如规范和权利要求中定义的2-氰基嘧啶化合物的自由形式或盐形式及在可能的情况下互变异构体形式，作为猫hepsin S活性的抑制剂。
• US7704996B2
  申请人：——

  公开号：US7704996B2

  公开（公告）日：2010-04-27
• Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2
  作者：Osamu Irie、Takatoshi Kosaka、Masashi Kishida、Junichi Sakaki、Keiichi Masuya、Kazuhide Konishi、Fumiaki Yokokawa、Takeru Ehara、Atsuko Iwasaki、Yuki Iwaki、Yuko Hitomi、Atsushi Toyao、Hiroki Gunji、Naoki Teno、Genji Iwasaki、Hajime Hirao、Takanori Kanazawa、Keiko Tanabe、Peter C. Hiestand、Marzia Malcangio、Alyson J. Fox、Stuart J. Bevan、Mohammed Yaqoob、Andrew J. Culshaw、Terance W. Hart、Allan Hallett

  DOI：10.1016/j.bmcl.2008.08.067

  日期：2008.10

  We describe here orally active and brain-penetrant cathepsin S selective inhibitors, which are virtually devoid of hERG K(+) channel affinity, yet exhibit nanomolar potency against cathepsin S and over 100-fold selectivity to cathepsin L. The new non-peptidic inhibitors are based on a 2-cyanopyrimidine scaffold bearing a spiro[3.5] non-6-yl-methyl amine at the 4-position. The brain-penetrating cathepsin S inhibitors demonstrate potential clinical utility for the treatment of multiple sclerosis and neuropathic pain. (c) 2008 Elsevier Ltd. All rights reserved.